V5med was established in 2024 with a primary focus on Medical Image AI. Leveraging cutting-edge AI technology, V5med collaboratively partnered with prestigious institutions such as Taipei Veterans General Hospital, National Taiwan University Hospital, and the Taiwan Lung Cancer Society. Together, they spearheaded the development of V5 Lung AI, an advanced lung cancer screening computer-aided detection (CAD) system.
V5 lung AI solution is well developed, and it is versatile and can accommodate multiple CT scanners and workstations, facilitating concurrent use by multiple users.
V5med’ve partnered with distributors worldwide, including Singapore. We aim to be global leader in AI lung cancer detection, with strategically expand from South East Asia, U.S.A, Latin America and Europe. In addition to our pioneering Lung AI capabilities, V5med remains dedicated to advancing lung cancer cytology analysis, COPD diagnostics, coronary artery calcification assessments, and AI conductor platforms. The ultimate aspiration is to solidify V5med's position as a global frontrunner in the field of image AI solutions. Empowered with vanguard AI technology, our mission is to save more lives in the world.